Insulin secretion-independent effects of GLP-1 on canine liver glucose metabolism do not involve portal vein GLP-1 receptors.

No abstract is available for this paper.

• Publication year

  2005

• Venue

  American Journal of Physiology - Gastrointestinal and Liver Physiology

• Publication date

  2005-11-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1152/AJPGI.00121.2005PMID 16051922PMCID PMC2435373
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Synergistic effect of portal glucose and glucagon-like peptide-1 to lower systemic glucose and stimulate counter-regulatory hormones

  2005cited by this paper
• Cell signalling of glucagon-like peptide-1 action in rat skeletal muscle.

  2004cited by this paper
• Insulin-independent effects of GLP-1 on canine liver glucose metabolism: duration of infusion and involvement of hepatoportal region.

  2004cited by this paper
• Effects of intraduodenal fatty acids on appetite, antropyloroduodenal motility, and plasma CCK and GLP-1 in humans vary with their chain length.

  2004cited by this paper
• Circulation and Degradation of GIP and GLP-1

  2004cited by this paper
• Effect of intraportal glucagon-like peptide-1 on glucose metabolism in conscious dogs.

  2003cited by this paper
• Direct and indirect effects of insulin on glucose uptake and storage by the liver.

  2002cited by this paper
• GLP-1-(9-36) amide reduces blood glucose in anesthetized pigs by a mechanism that does not involve insulin secretion.

  2002cited by this paper
• Glucagon-like peptide-1 (GLP-1) and glucose metabolism in human myocytes.

  2002cited by this paper
• Exendin-4 increases insulin sensitivity via a PI-3-kinase-dependent mechanism: contrasting effects of GLP-1.

  2002cited by this paper
• Glucose competence of the hepatoportal vein sensor requires the presence of an activated glucagon-like peptide-1 receptor.

  2001influential reference
• Impaired incretin response after a mixed meal is associated with insulin resistance in nondiabetic men.

  2001influential reference
• Effect of glucagon-like peptide 1(7-36) amide on glucose effectiveness and insulin action in people with type 2 diabetes.

  2000cited by this paper
• Portal GLP-1 administration in rats augments the insulin response to glucose via neuronal mechanisms.

  2000cited by this paper
• The hepatic vagal reception of intraportal GLP-1 is via receptor different from the pancreatic GLP-1 receptor.

  2000cited by this paper
• Rapid reversal of the effects of the portal signal under hyperinsulinemic conditions in the conscious dog.

  1999cited by this paper
• Glucagon-Like Peptide 1 Elevates Cytosolic Calcium in Pancreaticβ -Cells Independently of Protein Kinase A1.

  1999cited by this paper
• The glucagon-like peptides.

  1999cited by this paper
• Rapid reversal of the effects of the portal signal under hyperinsulinemic conditions in the conscious dog.

  1999cited by this paper
• Glucagon-like peptide 1 increases insulin sensitivity in depancreatized dogs.

  1999cited by this paper
• Glucagon-like peptide 1 elevates cytosolic calcium in pancreatic beta-cells independently of protein kinase A.

  1999cited by this paper
• GLP-1 action in L 6 myotubes is via a receptor different from the pancreatic GLP-1 receptor

  1998cited by this paper
• GLP-1 action in L6 myotubes is via a receptor different from the pancreatic GLP-1 receptor.

  1998cited by this paper
• Inositolphosphoglycans possibly mediate the effects of glucagon‐like peptide‐1(7‐36)amide on rat liver and adipose tissue

  1998cited by this paper
• Glucagon‐like peptide‐1 (GLP‐1): A gut hormone of potential interest in the treatment of diabetes

  1998cited by this paper
• Glucagon-like peptide-1-(7-36) amide and peptide YY mediate intraduodenal fat-induced inhibition of acid secretion in dogs.

  1998cited by this paper
• Insulinotropic hormone glucagon-like peptide-1-(7-37) appears not to augment insulin-mediated glucose uptake in young men during euglycemia.

  1998cited by this paper
• Exendin-4 agonist and exendin(9-39)amide antagonist of the GLP-1(7-36)amide effects in liver and muscle.

  1997cited by this paper
• Regulation of glucose transporters and hexose uptake in 3T3-L1 adipocytes: glucagon-like peptide-1 and insulin interactions.

  1997cited by this paper
• Glucagon-like peptide-1 inhibits gastric emptying via vagal afferent-mediated central mechanisms.

  1997cited by this paper
• Vagal hepatopancreatic reflex effect evoked by intraportal appearance of tGLP-1.

  1996cited by this paper
• Inositolphosphoglycans are possible mediators of the glucagon-like peptide 1 (7–36)amide action in the liver

  1996cited by this paper
• GLP-1 does not acutely affect insulin sensitivity in healthy man

  1996cited by this paper
• Inositolphosphoglycans and diacyglycerol are possible mediators in the glycogenic effect of GLP-1(7-36)amide in BC3H-1 myocytes.

  1996cited by this paper
• Enteral Enhancement of Glucose Disposition by Both Insulin-Dependent and Insulin-Independent Processes: A Physiological Role of Glucagon-Like Peptide I

  1995cited by this paper
• Glucagon-like peptide-1 and glucose-dependent insulin-releasing polypeptide plasma levels in response to nutrients.

  1995cited by this paper
• Glucagon-like peptide-1 binding to rat hepatic membranes.

  1995cited by this paper
• Glucagon-like peptide-1 binding to rat skeletal muscle.

  1995cited by this paper
• Disposition of a mixed meal by the conscious dog.

  1994cited by this paper
• Potent glycogenic effect of GLP-1(7–36)amide in rat skeletal muscle

  1994cited by this paper
• Divergent tissue-specific and developmental expression of receptors for glucagon and glucagon-like peptide-1 in the mouse.

  1994cited by this paper
• Glucagon-like peptide 1 enhances glucose tolerance both by stimulation of insulin release and by increasing insulin-independent glucose disposal.

  1994cited by this paper
• Presence and characterization of glucagon-like peptide-1(7-36) amide receptors in solubilized membranes of rat adipose tissue.

  1993cited by this paper
• Expression cloning of the pancreatic beta cell receptor for the gluco-incretin hormone glucagon-like peptide 1.

  1992cited by this paper
• Antidiabetogenic effect of glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus.

  1992cited by this paper
• Absence of insulinotropic glucagon‐like peptide‐I(7–37) receptors on isolated rat liver hepatocytes

  1991cited by this paper
• Intraportal glucose delivery alters the relationship between net hepatic glucose uptake and the insulin concentration.

  1991cited by this paper
• Receptors for glucagon-like peptide-1(7-36) amide on rat insulinoma-derived cells.

  1988cited by this paper
• Glucagon-like peptide I stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell line.

  1987cited by this paper
• Journal of Clinical Endocrinology and Metabolism Printed in U.S.A. Copyright © 1998 by The Endocrine Society Insulinotropic Hormone Glucagon-Like Peptide-1-(7–37) Appears Not to Augment Insulin-Mediated Glucose Uptake in Young Men during Euglycemia*

  year unknowncited by this paper

• Physiological and pharmacological actions of glucagon like peptide-1 (GLP-1) in domestic animals

  2022cites this paper
• Glucagon-like peptide-1 receptor-based therapeutics for metabolic liver disease.

  2022cites this paper
• The Regulation of Peripheral Metabolism by Gut-Derived Hormones

  2019cites this paper
• The effects of add-on exenatide to insulin on glycemic variability and hypoglycemia in patients with type 1 diabetes mellitus

  2018cites this paper
• Bile Acid Signaling Pathways from the Enterohepatic Circulation to the Central Nervous System

  2017cites this paper
• Gastrointestinal and Cardiovascular Effects of Incretin-Based Therapies: Friend or Foe?

  2017cites this paper
• Gastrointestinal actions of glucagon‐like peptide‐1‐based therapies: glycaemic control beyond the pancreas

  2016cites this paper
• The Effect of Fluid Dairy Products on Satiety, Food Intake and Glycemic Regulation in Children

  2016cites this paper
• Exenatide improves both hepatic and adipose tissue insulin resistance: A dynamic positron emission tomography study

  2016influential citation
• Hepato-Incretin Function of GLP-1: Novel Concept and Target in Type 1 Diabetes

  2015cites this paper
• Vagal mediation of GLP-1's effects on food intake and glycemia.

  2015cites this paper
• Physiological aspects of the combination of insulin and GLP-1 in the regulation of blood glucose control.

  2015cites this paper
• Oral glucose tolerance testing to modulate plasma amyloid levels: A novel biomarker

  2015cites this paper
• Milk and its Components in the Regulation of Short-term Appetite, Food Intake and Glycemia in Young Adults

  2014cites this paper
• The Effect of Whey Protein on Short-term Food Intake and Post-meal Glycemic Regulation in Young Adults

  2014cites this paper
• Absence of Glucagon and Insulin Action Reveals a Role for the GLP-1 Receptor in Endogenous Glucose Production

  2014cites this paper
• Effects of sitagliptin on ectopic fat contents and glucose metabolism in type 2 diabetic patients with fatty liver: A pilot study

  2014cites this paper
• Absence of Glucagon and Insulin Action Reveals a Role for the Glucagon-like Peptide-1 Receptor in Endogenous Glucose Production

  2014influential citation
• Glucagon-like peptide-1 reduces contractile function and fails to boost glucose utilization in normal hearts in the presence of fatty acids.

  2013cites this paper
• Effects of intraportal exenatide on hepatic glucose metabolism in the conscious dog.

  2013cites this paper
• Vildagliptin preserves the mass and function of pancreatic β cells via the developmental regulation and suppression of oxidative and endoplasmic reticulum stress in a mouse model of diabetes

  2012cites this paper
• Obesity and Appetite Control

  2012cites this paper
• Pancreatic GLP-1 receptor activation is sufficient for incretin control of glucose metabolism in mice.

  2012cites this paper
• Glucagon‐like peptide‐1 receptor activation stimulates hepatic lipid oxidation and restores hepatic signalling alteration induced by a high‐fat diet in nonalcoholic steatohepatitis

  2011cites this paper
• Hepatic Metabolic Dysfunctions in Type 2 Diabetes: Insulin Resistance and Impaired Glucose Production and Lipid Synthesis

  2011cites this paper
• Effect of exenatide on splanchnic and peripheral glucose metabolism in type 2 diabetic subjects.

  2011cites this paper
• Targeting type 2 diabetes.

  2011cites this paper
• Glucagon as a Critical Factor in the Pathology of Diabetes

  2011influential citation
• Incretin Concepts

  2010influential citation
• Novel Glucagon-like Peptide-1 Analog Delivered Orally Reduces Postprandial Glucose Excursions in Porcine and Canine Models

  2010cites this paper
• Pleiotropic actions of the incretin hormones.

  2010cites this paper
• Featured Insulin-like actions of glucagon-like peptide-1 : a dual receptor hypothesis

  2010cites this paper
• Translating TCF7L2: from gene to function

  2009cites this paper
• Targeting the CNS to treat type 2 diabetes

  2009cites this paper
• Inhibition of Dipeptidyl Peptidase-4 by Vildagliptin During Glucagon-Like Peptide 1 Infusion Increases Liver Glucose Uptake in the Conscious Dog

  2009cites this paper
• Current strategies for the inhibition of hepatic glucose production in type 2 diabetes.

  2009influential citation
• GLP-1 et systme nerveux : un mcanisme de son action antidiabtique

  2008cites this paper
• Commonality Between Diabetes and Alzheimer’s Disease and A New Strategy for the Therapy

  2008cites this paper
• Endocrinology of the Gastrointestinal Tract and Modulation of Satiety: Specific Focus on Glucagon-Like Peptide-1

  2008cites this paper
• Measuring the effect of a study meal on portal concentrations of glucagon-like peptide 1 (GLP-1) in non diabetic and diabetic patients with liver cirrhosis: transjugular intrahepatic portosystemic stent shunt (TIPSS) as a new method for metabolic measurements.

  2008cites this paper
• Intraportally delivered GLP-1, in the presence of hyperglycemia induced via peripheral glucose infusion, does not change whole body glucose utilization.

  2008cites this paper
• The integrative role of CNS fuel-sensing mechanisms in energy balance and glucose regulation.

  2008cites this paper
• The effect of vagal cooling on canine hepatic glucose metabolism in the presence of hyperglycemia of peripheral origin.

  2007cites this paper
• Newly approved and promising antidiabetic agents.

  2007cites this paper
• Intraportal GLP-1 infusion increases nonhepatic glucose utilization without changing pancreatic hormone levels.

  2007cites this paper
• CNS GLP-1 regulation of peripheral glucose homeostasis.

  2007cites this paper
• Is Glucagon-like peptide-1, an agent treating diabetes, a new hope for Alzheimer’s disease?

  2007cites this paper
• The Glucagon‐Like Peptides

  2006cites this paper
• Improvement of Glucose Tolerance and Hepatic Insulin Sensitivity by Oligofructose Requires a Functional Glucagon-Like Peptide 1 Receptor

  2006cites this paper
• GLP-1 and type 2 diabetes: physiology and new clinical advances.

  2006cites this paper